Background: In recent years, there has been an ongoing discussion on the relationship between diabetes and driving. As driving performance will inevitably decline at lower levels of glycemia, patients' decision concerning driving or taking corrective action when hypoglycemia occurs immediately before or during driving, seems paramount.
Introduction
In recent years, there has been an ongoing discussion on the relationship between diabetes and driving, since (severe) hypoglycemia may impair driving performance, and thus traffic violations and accidents may occur 1 . Indeed, the group of Cox et al. has shown disrupted driving performance even at glycemic levels of 4.0-3.4 mmol/l 2,3 , As driving performance will inevitably decline at low levels of glycemia, patients' decision concerning driving or taking corrective action when hypoglycemia occurs immediately before or during driving, seems paramount. The decision to drive may be complicated by the fact that hypoglycemia induces cognitive dysfunction, and therefore decision making may be impaired [4] [5] [6] .
In previous studies in type 1 diabetic patients under experimental hypoglycemic conditions, only 22% of patients in a driving simulator pulled over or undertook corrective action while driving at 2.2 mmol/l 3 . During hypoglycemia (2.8 mmol/l), 22-38% of the patients judged that they could drive safely 7 . This perception was more frequent among older patients and females. However, in another study, corrective action was only associated with normal awareness of hypoglycemia, and not with age, gender, duration of disease or other diseaserelated factors 8 . In their natural environment, using hand-held computers, approximately 40% of patients with type 1 diabetes said they would drive when they estimated their own blood glucose at 3.9-3.3 mmol/l, or even below 2.2 mmol/l. With an actual blood glucose below 2.2 mmol/l, 38-47% decided to drive 9 . No distinction was made according to awareness of hypoglycemia. In the only study involving type 2 diabetic patients, 89% of insulin-using (type 1 and type 2) patients answered to a survey that they would stop when experiencing hypoglycemia during driving. However, 60% reported never to test blood glucose before driving or only when experiencing symptoms of hypoglycemia.
Twenty-five percent indicated that they considered blood glucose values below 4.0 mmol/l safe for driving 10 .
In the current study, we aimed to assess the decision to drive during moderate hypoglycemia (2.7 mmol/l) in controlled experimental conditions, objectively verifying hypoglycemia awareness, in patients with type 1 and patients with type 2 diabetes.
Methods

Subjects
All subjects were adults between the age of 20 and 65 years of age, who participated in a larger study on the effect of hypoglycemia on driving performance in a state-of-the-art driving simulator. Patients were recruited from the outpatient clinic of the University Medical Center Utrecht, Utrecht, the Netherlands. Eligibility criteria included at least two years of diabetes mellitus, absence of cardiovascular disease or neuropathy, visual acuity >16/20 in both eyes, possession of a driving license for at least two years, and at least 5000 miles driven in the past year. No subject could use medication influencing hypoglycemia counter regulation or the ability to drive. The study was approved by the institutional review board of the University Medical Center Utrecht, and all subjects gave written informed consent.
Procedure
Patients were withdrawn from long-and intermediate acting insulin for 24 hours before the study and managed with short-acting insulin. They completed a validated questionnaire on hypoglycemia awareness 11 . Subjects arrived at the TNO Human Factors Research Institute at 8:00 PM on the evening before the study. Two antecubital veins were cannulated. No caffeinated beverages were consumed after arrival. Subjects were given a bedtime snack at 11:00 PM, and remained fasting from bedtime until the end of the study. Nocturnal nearnormoglycemia was maintained, using a variable, low-dose insulin infusion 12 . In the morning, a hyperinsulinemic glucose clamp was started. Via one cannula insulin (Human Actrapid, Novo Nordisk, Gentofte, Denmark; in a 4% solution of the subject's own plasma in 0.9% saline) was infused at 2.0 mU/kg/min, (IVAC P2000, IVAC Corporation, San Diego, CA, USA) and dextrose 20% (IVAC 560, IVAC Corporation, San Diego, CA, USA) at a variable rate. Via the other cannula, arterialized venous blood samples were obtained every 5 minutes, using a heating sleeve to warm the arm to 55 °C. The cannula was kept patent with 0.9% saline. Plasma glucose was measured using a glucose oxidase method (YSI 2300 STAT, Yellow Springs Instruments, Yellow Springs, OH, USA). Subjects were blinded for their plasma glucose level during the experiment.
Subjects completed two sessions of three runs in the driving simulator, each run lasting a minimum of 8 minutes. The first driving session was driven with a constant plasma glucose concentration of 5.0 mmol/l. Subsequently plasma glucose was lowered to a constant plasma glucose concentration of 2.7 mmol/l. Upon achieving this plasma glucose concentration, but after at least 60 minutes, the second driving session was performed. At baseline and immediately before each driving session, blood was drawn to measure epinephrine levels (HPLC-essay, Chromesystems, Munich, Germany). Also, before each driving session, two questions were posed: 1. "Do you currently feel hypoglycemic?", with possible answers being "yes", "no" or "maybe". 2. "Would you currently drive in everyday life?", with possible answers being "yes", "maybe", "no" or "I would first measure my blood glucose". Subsequently, a semi-quantitative questionnaire was administered to assess hypoglycemic symptoms. Subjects rated each of the following hypoglycemic symptoms from 0 (none) to 6 (severe): palpitations, anxiety, tremor, sweating, cold hands, numb lips and dry mouth (autonomic symptoms); difficulty concentrating, blurred vision, impaired speech, and confusion (neuroglycopenic symptoms); difficulty breathing, painful legs, seeing yellow halos (dummy symptoms).
Statistical analysis
Assessment of hypoglycemia awareness Before data analysis, it was established for each patient whether there was a significant rise in epinephrine levels or symptom scores during hypoglycemia as compared to euglycaemia, defined as exceeding the 95% confidence limit observed during euglycemia, as previously described 13 . Patients were identified as having normal awareness for hypoglycemia, if there was a significant rise in both parameters. In addition, subjects were rated as hypoglycemia aware or unaware according to Clarke's questionnaire and according to the single question "To what extent can you tell by your symptoms that your sugar is low? (never, sometimes, often, always)" Analysis of the decision to drive In analyzing the question "Would you currently drive in every day life?" the answers "Yes" and "Maybe" while plasma glucose was 2.7 mmol/l (second driving session), were considered potentially dangerous, as patients would (possibly) drive in a hypoglycemic state. In this situation, "No" and "I would first measure my blood glucose", were considered safe, assuming that patients would take corrective action upon measuring a hypoglycemic value. To determine whether there was a significant difference in answers to the questions posed between various study groups, χ 2 -tests were performed. Other data will be presented as mean ± SD, with a two-sided 5% level of significance in Student's t-tests.
Results
Subjects
and hypoglycemia awareness Forty-five patients with type 1 diabetes mellitus and 20 patients with type 2 diabetes were enrolled in the study. Subjects were identified as having normal hypoglycemia awareness based on the combined criteria of both epinephrine levels and symptoms scores. Twenty-four of the type 1 diabetic patients were identified as having normal hypoglycemia awareness (T1Norm group), 21 type 1 diabetic patients had impaired hypoglycemia awareness (T1Imp group). All 20 patients with type 2 diabetes had normal hypoglycemia awareness (T2 group); twelve subjects used insulin, eight subjects used sulphonylureas. The type 2 diabetic patients were older than the subjects in the other study groups (Table 1) .
Euglycemia
Before the first driving session all study groups were euglycemic (plasma glucose 5.12 ± 0.6 mmol/l).
T1Norm group When asked whether they felt hypoglycemic, 22 patients in the T1Norm group (91.7%) stated they did not feel hypoglycemic, and 2 (8.3%) answered "Maybe". Yet, in response to the question whether they would currently drive in everyday life, 7 (29.2%) declared they would first measure their blood glucose before driving. Only 1 subject answered "Maybe" to the latter question (4.5%).
T1Imp group Four patients answered "Maybe" to the question about feeling hypoglycemic (19%), and 8 (38.1%) would first measure their blood glucose before driving, whereas 1 subject (4.8%) would "Maybe" drive.
T2 group One patient answered he was "Maybe" hypoglycemic (5%), all others answered "No" (95%). Two patients in this group stated they would first measure their blood glucose (10%), and 3 (15%) said they would not drive in their current condition.
Analysis of the decision to drive
During euglycemia, the decision not to drive (or to measure blood glucose before driving) was not made more frequently by patients in the T1Norm than in the T1Imp group (χ 2 =0.11; P=0.74), or by patients in the T2 group (χ 2 =0.36; P=0.55). This was no difference for patients using insulin (χ 2 =0.26; P=0.61), nor for patients using oral hypoglycemic agents (χ 2 =0.19; P=0.66).
Hypoglycemia
After the first driving sessions, hypoglycemia was induced with the hyperinsulinemic clamp (2.68 ± 0.29 mmol/l). The subjects' perception of their glycemic condition during hypoglycemia and their decision to drive are shown in Table 2 .
T1Norm group Fifteen of 24 subjects (62.5%) felt hypoglycemic. None of these subjects stated they would currently drive, but 1 (6.7%) stated "Maybe" he would drive. Three subjects would measure their blood glucose (20.0%) and 11 (73.3%) would not drive. Nine subjects (37.5%) stated they were "Maybe" hypoglycemic. Eight of them (88.9%) would first measure their blood glucose, and one (11.1%) would not drive.
T1Imp group Eight of 21 subjects (38.1%) stated they possibly were hypoglycemic. Five of these 8 subjects (62.5%) wanted to measure their blood glucose before driving, and 3 (37.5%) would not drive. Thirteen patients (61.9%) did not perceive hypoglycemia, 9 of whom (69.2%) acknowledged they would drive in everyday life. Three (23.1%) would measure their blood glucose prior to driving, and 1 subject (7.7%) would not drive.
T2 group
Of the 20 type 2 diabetic patients (all with normal hypoglycemia awareness), 11 (55.0%) answered that they felt hypoglycemic. Five (45.5%) of these patients would measure their blood glucose, and 6 (54.5%) would not drive at all. Of the 9 patients who stated they "Maybe" experienced hypoglycemia (45%), 3 (33.3%) would drive anyway in everyday life, and 2 (22.2%) would "Maybe" drive. On the other hand, 2 subjects would measure blood glucose and 2 would not drive (22.2%, respectively).
Analysis of the decision to drive
The answers "Yes" and "Maybe" were considered unsafe decisions during hypoglycemia, whereas the answers "No" and "I would first measure my blood glucose" were considered safe. Unsafe decisions were made more frequently in the T1Imp group than in the T1Norm group (χ 2 = 9.70; P=0.002).
Strikingly, the T2 patients also made unsafe decisions (decided to drive) more frequently during hypoglycemia than T1Norm patients (χ 2 =4.02; P=0.04). When comparing the T2 group to all type 1 diabetic patients there was no difference (χ 2 =0.06; P=0.81). In the T2 group, patients using oral hypoglycemic agents answered they would make an unsafe decision (drive) during perceived hypoglycemia more frequently than patients using insulin (χ 2 =4.44; P=0.04). When comparing T2 patients on oral hypoglycemic agents to all insulin users, the same trend was noted, but it did not reach statistical significance (χ 2 =3.73; P=0.054).
Hypoglycemia awareness questionnaire When hypoglycemia awareness was assessed with Clarke's hypoglycemia awareness questionnaire 11 , in the T1Norm group one subject was rated unaware. In the T1Imp group five subjects who answered "Maybe" and five subjects who answered "No" to the question "Do you currently feel hypoglycemic?" were rated as hypoglycemia aware according to Clarke 
Discussion
This is the first study to examine the decision to drive in diabetic patients according to objectively assessed hypoglycemia awareness, and the first experimental study with type 2 diabetic patients. This study led to two important findings. First, a striking finding is that many type 1 diabetes patients with impaired hypoglycemia awareness (43%) failed to decide not to drive during experimental hypoglycemia. As these patients were not conscious of their hypoglycemic condition, this seems comprehensible.
However, these decisions may lead to dangerous situations in traffic. Indeed, data of driving simulator studies of our study group indicate that safe driving is maintained at 2.7 mmol/l in type 1 diabetic patients with normal and impaired hypoglycemia awareness 14 and in type 2 diabetic patients with normal hypoglycemia awareness 15 . However, it is of no doubt that driving performance will inevitably deteriorate at lower levels of glycemia. Therefore, the decision not to initiate driving or to take appropriate action during driving (pull over and consume carbohydrates) when hypoglycemic, is of paramount importance. In the current study, only 1 of 24 patients (4.2%) with type 1 diabetes and normal hypoglycemia awareness chose to drive while (symptomatically) hypoglycemic.
Second, the perhaps most alarming finding pertains to type 2 diabetic patients. In spite of their normal hypoglycemia awareness, 25% of these patients decided to drive while positive or in doubt whether they were hypoglycemic. This was principally the case for patients on oral hypoglycemic agents. This is particularly worrying because of the large and increasing number of patients with type 2 diabetes. Several factors could play a role. First, as patients with type 2 diabetes experience hypoglycemia less frequently than patients with type 1 diabetes, they could be less familiar with the potential dangers. Second, for this very reason, patients may have received less education from doctors and nurses about hypoglycemia and driving, which is often conflicting 16 . These two possible explanations are supported by the fact that mainly patients on oral hypoglycemic agents make potentially dangerous decisions. Third, by the time that patients are diagnosed with type 2 diabetes, they are generally older than type 1 patients, and have driven for several decades. Consequently, their driving behavior has been well established, and therefore will be less affected by social pressure and education 17 .
There are indications that, although potentially dangerous decisions were made, the diabetic subjects in the current study were aware of impending hazards. Although legally regulated in some countries, dutch law does not require self-testing of blood glucose. Nevertheless, during euglycaemia, 25-43% of patients stated they would not drive without measuring their blood glucose first, or maybe not drive at all. However, this study meets certain limitations. It must be borne in mind that subjects were familiar with the fact that this was a study about diabetes and driving, and perhaps volunteered out of special attitudes towards driving. Furthermore, in some instances, although they were blinded for their plasma glucose, subjects may have given "socially desired" answers, instead of their true beliefs. Thus, the results in this study may underestimate true percentages of potentially dangerous decisions. Finally, in the analysis the answer "I would first measure my blood glucose" was considered "safe", assuming that patients would take corrective action upon measuring a hypoglycemic value. However, from previous research it is known that patients may consider values far below 4.0 mmol/l safe to engage in driving 10 .
In clinical practice, assessment of hypoglycemia awareness with the use of the hyperinsulinemic glucose clamp technique is rarely possible. However, in this study self-reported impaired hypoglycemia awareness as assessed with Clarke's validated questionniare 11 , or even with a single question, showed good correlation with unsafe decisions. However, a higher percentage of patients who were identified as having normal hypoglycemia awareness made unsafe decisions when the questionnaire was used (12.1 vs. 4.2%). Therefore, this method appears to be less accurate at identifying patients at increased risk of making dangerous decisions. Moreover, when patients become familiar with the questions and the potential consequences of their answers, they may adapt their answers accordingly.
Nevertheless, the questionnaire may be a helpful tool in clinical practice to estimate the risk of dangerous decision making.
In conclusion, in the current study, most patients with type 1 diabetes and normal awareness of hypoglycemia appear to make safe decisions concerning hypoglycemia and driving. In contrast, patients with type 1 diabetes and impaired awareness of hypoglycemia frequently decide to drive while hypoglycemic, as may be expected. Strikingly, patients with type 2 diabetes and normal hypoglycemia awareness frequently take potentially dangerous decisions as well, particularly when using oral hypoglycemic agents. This is particularly worrying in light of the increasing number of patients. Therefore early, clear and consistent education is imperative. Table 2 . Perception of glycemic condition during hypoglycemia (2.7 mmol/l) and decision to drive (n(%)). 
